Skip to content

High Flow Nasal Cannula to Prevent Deoxygenation During Induction of General Anesthesia in Cesarean Section

A Prospective Randomized Study of High Flow Nasal Cannula to Prevent Deoxygenation During Induction of General Anesthesia in Cesarean Section

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04438798
Enrollment
80
Registered
2020-06-19
Start date
2020-07-01
Completion date
2020-11-01
Last updated
2020-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypoxic Brain Injury, Maternal Death

Brief summary

Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE) using high flow oxygen therapy for preoxygenation and oxygen supplementation during apnoea has shown promising results

Detailed description

Eeffective preoxygenation followed by apnoeic oxygenation enables anaesthesiologists to safely prolong the apnoea time which is the time (seconds) of apnea following preoxygenation and muscle relaxation before to peripheral oxygen saturations (SpO2) decreases by 2%.

Interventions

OTHERF Group

In Group F, pregnant females will be preoxygenated with 100% oxygen using a tight-fitting face mask at a rate of 6 L/min for 3 min with end-tidal gas monitoring.

OTHERH Group

In Group H, high-flow humidified oxygen warmed to 37°C will be delivered through nasal cannula at the rate of 30 L/ min for 30 seconds then 50 liters per minute for a further 150 seconds.

Sponsors

Alexandria University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* pregnant females * Of American Society of Anesthesiologists (ASA) physical Status I and II * For elective cesarean section under general anesthesia

Exclusion criteria

* with room air saturation of \<98% * anticipated difficult airway * anticipated obstetric risk factor or precious baby * chronic obstructive pulmonary disease * thyrotoxicosis * pheochromocytoma * hyperkalaemia * significant cardiac illness

Design outcomes

Primary

MeasureTime frameDescription
measure the time of safe apnea10 minutes after inductionThe apnea time will start from the onset of cessation of breathing as evidenced by a flat line in the capnogram with the absence of chest movements

Countries

Egypt

Contacts

Primary ContactRehab A. Abd Elaziz, Ass. Prof.
trcium2002@yahoo.com01001073703

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026